Relevant bibliographies by topics / Non-benzodiazepine hypnotics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Non-benzodiazepine hypnotics'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non-benzodiazepine hypnotics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non-benzodiazepine hypnotics"

1

Longo, V. G. "Non-benzodiazepine anxiolytics and hypnotics." Pharmacology Biochemistry and Behavior 29, no. 4 (April 1988): 761. http://dx.doi.org/10.1016/0091-3057(88)90201-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Davies, Dilys R. "A Comparison of Hypnotic and Non-hypnotic Users in the Group Therapy of Insomnia." Behavioural Psychotherapy 19, no. 2 (April 1991): 193–204. http://dx.doi.org/10.1017/s0141347300012222.

Full text
Abstract:
The present study evaluated the effectiveness of a multiple treatment approach to the group treatment of hypnotic and non-hypnotic taking insomniacs. Twenty subjects sequentially assigned into four groups attended weekly group therapy over a period of 11–13 weeks. Pre- and post-treatment comparisons indicated an overall improvement of the total sample on measures of general health, benzodiazepine related symptom reduction, reduction from hypnotic sedative medication as well as on measures of the quality and quantity of sleep. Overall there was a marked similarity between hypnotic and non-hypnotic users on the measures both before and after treatment. Psychological approaches are suggested as an effective alternative to the prescription of sedative-hypnotics to both recent and chronic insomnia sufferers. The implications of the findings are discussed.
APA, Harvard, Vancouver, ISO, and other styles
3

Dolder, Christian, Michael Nelson, and Jonathan McKinsey. "Use of Non-Benzodiazepine Hypnotics in the Elderly." CNS Drugs 21, no. 5 (2007): 389–405. http://dx.doi.org/10.2165/00023210-200721050-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cunnington, D. "Non-benzodiazepine hypnotics: do they work for insomnia?" BMJ 346, jan02 1 (January 2, 2012): e8699-e8699. http://dx.doi.org/10.1136/bmj.e8699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nguyen, PharmD, Van, and Christopher M. Herndon, PharmD, BCACP. "Impact of non-benzodiazepine sleep hypnotics on opioid overdose risk." Journal of Opioid Management 16, no. 6 (November 1, 2020): 400. http://dx.doi.org/10.5055/jom.2020.0605.

Full text
Abstract:
Increasing concerns regarding concomitant use of benzodiazepines with opioids have been addressed by FDA drug safety communications and are increasingly recognized amongst prescribers. However, non-benzodiazepine sleep hypnotics continue to be prescribed with opioids.
APA, Harvard, Vancouver, ISO, and other styles
6

Jiang, Xia, Wang, Zhou, Jiang, Diwan, and Xu. "Insomnia, Benzodiazepine Use, and Falls among Residents in Long-term Care Facilities." International Journal of Environmental Research and Public Health 16, no. 23 (November 21, 2019): 4623. http://dx.doi.org/10.3390/ijerph16234623.

Full text
Abstract:
Background: Falls are leading cause of injury among older people, especially for those living in long-term care facilities (LTCFs). Very few studies have assessed the effect of sleep quality and hypnotics use on falls, especially in Chinese LTCFs. The study aimed to examine the association between sleep quality, hypnotics use, and falls in institutionalized older people. Methods: We recruited 605 residents from 25 LTCFs in central Shanghai and conducted a baseline survey for sleep quality and hypnotics use, as well as a one-year follow-up survey for falls and injurious falls. Logistic regression models were applied in univariate and multivariate analysis. Results: Among the 605 participants (70.41% women, mean age 84.33 ± 6.90 years), the one-year incidence of falls and injurious falls was 21.82% and 15.21%, respectively. Insomnia (19.83%) and hypnotics use (14.21%) were prevalent. After adjusting for potential confounders, we found that insomnia was significantly associated with an increased risk of falls (adjusted risk ratio (RR): 1.787, 95% CI, 1.106–2.877) and the use of benzodiazepines significantly increased the risk of injurious falls (RR: 3.128, 95% CI, 1.541–6.350). Conclusion: In elderly LTCF residents, both insomnia and benzodiazepine use are associated with an increased risk of falls and injuries. Adopting non-pharmacological approaches to improve sleep quality, taking safer hypnotics, or strengthening supervision on benzodiazepine users may be useful in fall prevention.
APA, Harvard, Vancouver, ISO, and other styles
7

Perrault, Ghislaine, Eliane Morel, David J. Sanger, and Branimir Zivkovic. "Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics." European Journal of Pharmacology 187, no. 3 (October 1990): 487–94. http://dx.doi.org/10.1016/0014-2999(90)90375-g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Griebel, Guy, Ghislaine Perrault, and David J. Sanger. "Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents." Journal of Psychopharmacology 12, no. 4 (July 1998): 356–65. http://dx.doi.org/10.1177/026988119801200405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Manolis, Theodora A., Antonis A. Manolis, Evdoxia J. Apostolopoulos, Helen Melita, and Antonis S. Manolis. "Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside." Current Vascular Pharmacology 19, no. 2 (December 30, 2020): 210–32. http://dx.doi.org/10.2174/1570161118666200325102411.

Full text
Abstract:
: Sleep is essential to and an integral part of life and when lacking or disrupted, a multitude of mental and physical pathologies ensue, including cardiovascular (CV) disease, which increases health care costs. Several prospective studies and meta-analyses show that insomnia, short (<7h) or long (>9h) sleep and other sleep disorders are associated with an increased risk of hypertension, metabolic syndrome, myocardial infarction, heart failure, arrhythmias, CV disease risk and/or mortality. The mechanisms by which insomnia and other sleep disorders lead to increased CV risk may encompass inflammatory, immunological, neuro-autonomic, endocrinological, genetic and microbiome perturbations. Guidelines are emerging that recommend a target of >7 h of sleep for all adults >18 years for optimal CV health. Treatment of sleep disorders includes cognitive-behavioral therapy considered the mainstay of non-pharmacologic management of chronic insomnia, and drug treatment with benzodiazepine receptor agonists binding to gamma aminobutyric acid type A (benzodiazepine and non-benzodiazepine agents) and some antidepressants. However, observational studies and meta-analyses indicate an increased mortality risk of anxiolytics and hypnotics, although bias may be involved due to confounding and high heterogeneity in these studies. Nevertheless, it seems that the risk incurred by the non-benzodiazepine hypnotic agents (Z drugs) may be relatively less than the risk of anxiolytics, with evidence indicating that at least one of these agents, zolpidem, may even confer a lower risk of mortality in adjusted models. All these issues are herein reviewed.
APA, Harvard, Vancouver, ISO, and other styles
10

Undén, M., and B. Roth Schechter. "Next day effects after nighttime treatment with zolpidem: a review." European Psychiatry 11, S1 (1996): 21s—30s. http://dx.doi.org/10.1016/0924-9338(96)80465-2.

Full text
Abstract:
SummaryThe purpose of this review was to analyze the literature for potential next-day residual effects of zolpidem, a non-benzodiazepine hypnotic, following nighttime administration. Based on more than 30 international clinical trials involving more than 2,600 subjects/patients, it can be concluded that at the recommended doses of zolpidem 10 mg for adults and zolpidem 5 mg for the elderly, at single or repeated dosing, in healthy subjects or insomniac patients, zolpidem appears to induce minimal next-day residual effects. As for all sedative hypnotics, zolpidem is indicated for the short-term treatment of insomnia and is recommended to be taken only when the patient is able to get a full night's sleep before resuming usual activities.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non-benzodiazepine hypnotics"

1

Jain, Gauri. "Current prescribing patterns and use of non-benzodiazepine hypnotics in a retail environment." Thesis, 2009. http://hdl.handle.net/10539/6459.

Full text
Abstract:
Abstract Non-benzodiazepine drugs such as zopiclone and zolpidem are alternatives to treatment of insomnia, but are recommended only for short-term treatment. The objectives of the study were to evaluate the prescribing patterns and usage of these drugs. Method: Data was collected from Clicks Rosebank Pharmacy. One hundred (100) patients presenting with prescriptions for either zolpidem or zopiclone were followed over a period of seven months and data was collected regarding: demographic characteristics of patients; drug and dose distribution; ICD10 codes; prescriber characteristics; period of use; and whether use was continuous or as needed (uninterrupted or interrupted). All data was collected from the Unisolv computer system. Over a period of one year, total prescriptions received for all drugs were compared to the total number of zopiclone/zolpidem prescriptions received to gauge whether there was any seasonal variation in hypnotic use. Results: In each age group, excluding 20 years and below, the number of females was greater than males. The mean age of all patients between the ages of 21 and 80 years was 53.1 years. Out of 100 patients, 85 (85%), used either zolpidem 10mg or zopiclone 7.5mg, which are the standard doses. The most common ICD 10 code observed was G47.0, Disorders of initiating and maintaining sleep [insomnias], occurring in 52 (52%) of 100 prescriptions. Of the 100 initial prescriptions, 68 (68%) were prescribed by General Practitioners, while 32 (32%) were prescribed by Specialists. Thirty of the 100 patients (30%) used one of the drugs for the full seven months; twenty two patients (22%) used one of the drugs for a period of one month or less; and the remaining 48 patients (48%) used a hypnotic for a total of two to six months. The number of patients who used a hypnotic in an interrupted manner, with each period of use of one month or less duration, was 34 (34%). The number of patients who used a hypnotic for at least one uninterrupted period of more than 1 month s duration was 66 (66%). Over a period of 12 months, prescriptions for either zolpidem or zopiclone represented 3.17% of total prescriptions. There was no significant seasonal fluctuation in hypnotic use. Conclusion: The majority of patients used one of the two hypnotics in an uninterrupted manner, and over a long term as well. Despite numerous cautions in the literature, these medications are still being prescribed and used in a manner contrary to existing guidelines.
APA, Harvard, Vancouver, ISO, and other styles
2

Martin, Philippe. "Evaluation of direct-to-patient educational approaches for reducing inappropriate sedative-hypnotic use in community-dwelling older adults." Thèse, 2017. http://hdl.handle.net/1866/21206.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Non-benzodiazepine hypnotics"

1

Istituto superiore di sanità (Italy), ed. Non-benzodiazepine anxiolytics and hypnotics: Symposium, Istituto superiore di sanità : abstract book. Rome: Istituto superiore di sanità, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

O’Dowd, Mary Alice, and Maria Fernanda Gomez. Insomnia and HIV: A Biopsychosocial Approach. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0023.

Full text
Abstract:
Insomnia is a common complaint across populations and can influence health in many ways. Individuals with HIV may be at higher risk for insomnia owing to direct effects of the virus, pain, psychiatric comorbidities, and other health- and treatment-related issues and lifestyles. This chapter reviews the physiology of healthy sleep and sleep hygiene and addresses assessment and treatment of insomnia in persons with HIV. Careful interview of a patient and accompanying family or friends with the Epworth Sleepiness Scale or Pittsburg Sleep Quality Index may help define the nature of the insomnia and target interventions. Treatment for insomnia can include a form of cognitive-behavioral therapy designed specifically for insomnia as well as education aimed at restructuring bedtime habits in order to promote better sleep. Medication use, such as benzodiazepines, melatonin, orexin, and non-benzodiazepine hypnotics, in this population must take into consideration the specific risks and benefits these medications may present in persons with HIV.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Non-benzodiazepine hypnotics"

1

Monti, Jaime M., and Daniel Monti. "Non-benzodiazepine Hypnotics." In Encyclopedia of Psychopharmacology, 1134–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lader, Malcolm. "Anxiolytics and hypnotics." In New Oxford Textbook of Psychiatry, 1178–84. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199696758.003.0152.

Full text
Abstract:
In many countries the drug treatment of both anxiety and insomnia still largely revolves around the use of the benzodiazepines. Nevertheless, controversy and disagreement still rage about the risk–benefit ratio of compounds in this area. Short-term use in both indications is well established, with a favourable database as a rationale for this approach. However, long-term use is still only researched in a limited way. While both the efficacy and safety of long-term use remain unclear, acceptance of current guidelines limiting the use of benzodiazepines seems wise. The advent of the SSRIs as anxiolytics has driven a wedge between the treatment methods for anxiety and insomnia. Anxiety can be treated just as effectively with an SSRI (and probably, pregabalin) as with a benzodiazepine, and more safely. The treatment of insomnia still relies on the benzodiazepines until the risk–benefit ratio of newer drugs such as the melatonin-related compounds becomes clear. Nevertheless, in the author's opinion the most important outstanding issue is the relationship between drug and non-drug treatments. The management of anxiety disorders and of insomnia is complex and is hampered by a dearth of information concerning the relative merits of various treatment modalities. Much research is also needed on the optimum strategies for combining all the therapies available to us, and on identifying predictors of response. Developments in the neuropharmacology of insomnia hold out the promise of new compounds with novel and perhaps more effective modes of action. With respect to anxiety disorders, a major shift of emphasis has followed the demonstration of the efficacy of the SSRIs.
APA, Harvard, Vancouver, ISO, and other styles
3

Moul, Douglas E., Charles M. Morin, Daniel J. Buysse, Charles F. Reynolds, and David J. Kupfer. "Treatments for Insomnia and Restless Legs Syndrome." In A Guide to Treatments that Work, 611–40. Oxford University Press, 2007. http://dx.doi.org/10.1093/med:psych/9780195304145.003.0022.

Full text
Abstract:
Treating a chief complaint of inability to sleep is a core problem in psychiatric practice, together with treating other comorbid physical or mental disorders. The treatments for insomnia and restless legs syndrome (RLS) are well within the scope of psychiatric practice. Treatments for insomnia have been controversial over the past several decades, with practice patterns being driven partly by nonmedical influences operating in the setting of limited data. In recent years, the need to consider both cognitive-behavioral and pharmacological approaches together has become more apparent, with less insistence on strict either-or approaches. Clinical trial data clearly point to the efficacy of cognitive-behavioral approaches such as stimulus control, bed restriction, and related approaches. The literature on the short-term efficacy of benzodiazepine receptor agonists (BZRAs) as hypnotics has strengthened. There is a great amount of use of non-BZRAs as hypnotics, even though there are limited studies supporting their use. For RLS, the use of low-dose dopamine agonists has been substantially supported in Type 1 clinical trials. For iron-deficiency-induced RLS, iron replacement is strongly encouraged. Approaches such as using benzodiazepines are second-line treatments. Limited support for the use of gabapentin and carbamazepine is available, but the centuries-old approach of using opiates for the treatment of RLS remains a third-line approach.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non-benzodiazepine hypnotics' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography